AI Analyst Summary
MeiraGTx is a clinical-stage gene therapy company experiencing a transformational revenue inflection — YoY revenue growth of over 8,600% points to a landmark licensing or partnership milestone that has fundamentally re-rated near-term commercial prospects. All 7 covering analysts rate the stock a Buy with unanimous conviction, and the consensus price target of $29.43 implies over 117% upside from current levels. The primary risk is that forward earnings remain deeply negative, meaning sustained profitability depends entirely on pipeline execution and the durability of recent revenue recognition, which may be non-recurring.
Fundamentals
Pe
Trailing P/E: 15.5x (Forward P/E: -9.7x) · 3.0/5
Trailing P/E of 15.5x appears attractive on the surface and is below typical biotech sector multiples, but the deeply negative forward P/E signals that current profitability is not expected to persist — likely a one-time or irregular earnings event. This makes the trailing figure misleading as a valuation anchor.
Peg
N/A · 3.0/5
No PEG ratio available due to irregular earnings profile. Revenue growth of 8,608.6% YoY suggests a transformational inflection, but without a reliable earnings growth denominator, PEG cannot be meaningfully calculated. Scored neutral per guidelines.
Analyst Rating
Strong Buy consensus (1.3) · 5.0/5
Unanimous bullish conviction — 7 Buy ratings, 0 Hold, 0 Sell across 7 analysts. A consensus rating of 1.3 on the inverted scale maps to the top score tier. Analyst count exceeds the 5-analyst threshold, making this signal fully credible.
Earnings Trend
Revenue growth +8,608.6% YoY; EPS trend N/A · 4.0/5
Extraordinary revenue growth of over 8,600% YoY signals a major commercial or partnership milestone — likely a licensing deal or first meaningful product revenue. EPS trend is not available due to loss-making history, but the revenue inflection is a strong positive signal. Scored 4 rather than 5 given earnings remain negative on a forward basis and growth sustainability is unproven.
Price Target Beat
2 of 4 quarters beat · 2.0/5
EPS beat rate of 2 out of 4 quarters is below average. Only 4 quarters of data are available (insufficient for the full 8-quarter model), but the available data leans below expectations. This reflects inconsistent near-term execution relative to analyst estimates.
Management
Mixed execution signals · 3.0/5
The massive revenue inflection suggests management has secured a significant commercial agreement or milestone payment, which is a positive capital allocation signal. However, below-average EPS beat consistency and a deeply negative forward earnings outlook temper confidence. Scored neutral — strong strategic moves but inconsistent quarterly delivery.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Start free for 3 days →
No credit card. Then $9/month. Cancel anytime.
How Compass scores stocks
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.